Preventing anal cancer in people living with HIV
Official title: Prevention of anal cancer in People Living with HIV (PLWH)
Funded at Wm S. Middleton Memorial Veterans Hosp · NIH-10948112 · Data updated 2026-11-12
This study is looking for better ways to prevent anal cancer in people with HIV by testing a new treatment for precancerous conditions, hoping to find options that work well and have fewer side effects.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wm S. Middleton Memorial Veterans Hosp NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project start | October 1, 2021 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| NIH project number | 5I01BX005608-04 |
| Project ID | NIH-10948112 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults living with HIV who are at risk for anal dysplasia or anal cancer.
✕Less likely to help
Patients who do not have HIV or those without precancerous anal conditions may not benefit from this research.
What this research studies
This research focuses on preventing anal cancer, which is increasingly common among individuals living with HIV, particularly due to the effects of human papillomaviruses (HPVs). The study aims to improve treatment for precancerous anal conditions known as anal dysplasia, which currently have high recurrence rates and side effects. By utilizing a new mouse model and exploring the effects of HIV protease inhibitors, the research seeks to develop a topical treatment that targets the underlying mechanisms of cancer development. Patients may benefit from innovative therapies that could reduce the risk of progressing to anal cancer.
Why it matters
Potential benefit: If successful, this research could lead to effective treatments that significantly lower the incidence of anal cancer in people living with HIV.
How similar studies have gone: Previous research has shown promise in repurposing HIV protease inhibitors for cancer prevention, indicating a potential for success in this novel approach.
Where this research is happening
-
Wm S. Middleton Memorial Veterans Hosp
Madison, United States Active
Researchers
- Principal investigator: Carchman, Evie — Wm S. Middleton Memorial Veterans Hosp
- Study coordinator: Carchman, Evie
Related research
Other NIH-funded projects on the same topics.
-
Integrated approach to preventing anal cancer in HIV+ MSM through screening and treatment of HSIL
This project tests a streamlined plan to prevent anal cancer in people living with HIV by screening for HSIL and treating it at clinics serving MSM.
-
Preventing anal cancer in people living with HIV
A topical form of HIV protease inhibitors is being tried to clear precancerous anal changes in people living with HIV.
-
Screening strategies to find anal cancer precursors in high-risk people
Researchers will study markers from DNA methylation and immune signals to better identify people at risk for anal cancer before it develops.
-
Integrated approach to preventing anal cancer in HIV-positive MSM through HSIL screening and treatment
This project tests a proven HSIL screening-and-treatment approach to prevent anal cancer in men living with HIV, using Ghana/Nigeria-based sites to learn how to implement it broadly.
-
Better screening for anal cancer in people at higher risk
This project looks for biological and immune signals that could spot early precancerous changes in people at high risk for anal cancer.
-
Screen-and-treat program to prevent anal cancer in people with HIV
This project offers regular anal screening and treatment to men who have sex with men living with HIV to lower their risk of anal cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.